What is Artelo Biosciences Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Artelo Biosciences's cash to debt ratio for the quarter that ended in Mar. 2024 was 59.91.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Artelo Biosciences could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.
The historical rank and industry rank for Artelo Biosciences's Cash-to-Debt or its related term are showing as below:
ARTL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.37 Med: No Debt Max: No Debt
Current: 59.91
During the past 10 years, Artelo Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.37. And the median was No Debt.
Artelo Biosciences Cash-to-Debt Historical Data
The historical data trend for Artelo Biosciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Artelo Biosciences Cash-to-Debt Chart
|
Artelo Biosciences Annual Data
|
|
Trend |
Aug14 |
Aug15 |
Aug16 |
Aug17 |
Aug18 |
Aug19 |
Aug20 |
Aug21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
|
|
No Debt |
No Debt |
105.95 |
278.30 |
453.30 |
|
Artelo Biosciences Quarterly Data
|
|
May19 |
Aug19 |
Nov19 |
Feb20 |
May20 |
Aug20 |
Nov20 |
Feb21 |
May21 |
Aug21 |
Nov21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
297.75 |
349.78 |
402.00 |
453.30 |
59.91 |
Competitive Comparison of Artelo Biosciences's Cash-to-Debt
For the Biotechnology subindustry, Artelo Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's Cash-to-Debt falls into.
Artelo Biosciences Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Artelo Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Artelo Biosciences's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artelo Biosciences (Artelo Biosciences) Business Description
Traded in Other Exchanges
N/A
Address
505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
Executives
| Gregory D. Gorgas |
director, officer: See Remarks |
888 PROSPECT, SUITE 210, LA JOLLA CA 92037 |
| Tamara A Seymour |
director |
C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008 |
| Gregory Reyes |
director |
200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922 |
| Matsui Connie |
director |
3030 CALLAN RD, SAN DIEGO CA 92121 |
| John W Beck |
director |
C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067 |
| Robert Martin Emanuele |
director |
|
| David J Moss |
10 percent owner |
C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702 |
| Georgia Erbez |
director |
6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
| Steven Kelly |
director |
C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
| Douglas Blayney |
director |
C/O ARTELO BIOSCIENCES, INC., 888 PROSPECT ST, SUITE 210, LA JOLLA CA 92037 |
| Peter Michael O'brien |
10 percent owner |
C/O ARTELO BIOSCIENCES, INC., 888 PROSPECT ST, SUITE 210, LA JOLLA CA 92037 |
Artelo Biosciences (Artelo Biosciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARTL has been successfully added to your